# A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

> **NCT02258542** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2133 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Benralizumab
- **BIOLOGICAL:** Benralizumab

## Key facts

- **NCT ID:** NCT02258542
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-19
- **Primary completion:** 2017-10-18
- **Final completion:** 2018-07-02
- **Target enrollment:** 2133 (ACTUAL)
- **Last updated:** 2019-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02258542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02258542, "A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02258542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*